Navigation Links
Global Biomarkers Industry
Date:9/8/2011

NEW YORK, Sept. 8, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Biomarkers Industry

http://www.reportlinker.com/p0611080/Global-Biomarkers-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

This report analyzes the worldwide markets for Biomarkers in US$ Million by the following Technologies and Services: Technologies - Emerging Biomarker Technologies (Imaging biomarkers, Proteomics, Transcriptomics, & Bioinformatics), Conventional Biomarker Technologies - (Immunodiagnostics, & Molecular Diagnostics), and Others; Services - Clinical Biomarker Services, Specimen Preparation, and Bioinformatics and Others (miRNA Analysis and Others). The total market is also analyzed by the following Application Areas: Biomarker Discovery, Clinical Drug Development, and Diagnostics Techniques (Molecular). Key Therapeutic Areas also analyzed in the report include Oncology, Cardiology, CNS, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2008 through 2017. The report profiles 204 companies including many key and niche players such as Abbott Laboratories, Affymetrix, Inc., Agilent Technologies, Inc., Alexion Pharmaceuticals, Beckman Coulter, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BioMerieux, Bruker Corporation, Caprion Proteomics, Inc., Clarient Inc., Compugen, Ltd., Correlogic Systems, Inc., DiagnoCure, Inc., Epigenomics AG, GE Healthcare, Gene Logic, Genedata AG, Gen-Probe Inc., GlaxoSmithKline Plc, Hitachi Medical Corporation, Illumina, Inc., LabCorp., Life Technologies Corporation, Merck & Co. Inc., Metabolon, Inc., Myriad Genetics, Inc., Novartis International AG, Panacea Laboratories, Pfizer, Inc., Philips Healthcare, QIAGEN NV, Quest Diagnostic, Inc., Quest Diagnostics Company, Roche Diagnostics Corp., Rubicon Genomics, Inc., Rules-Based Medicine, Inc., and Siemens Healthcare Diagnostics, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Data Interpretation & Reporting Level 2

Quantitative Techniques & Analytics 3

Product Definition and Scope of Study 3

Definitions 4

Biomarker Technologies 4

Emerging Biomarker Technologies 4

Proteomics 4

Transcriptomics 5

Imaging biomarkers 5

Bioinformatics 5

Conventional Biomarker Technologies 5

Molecular Diagnostics 5

Immunodiagnostics 6

Other Biomarker Technologies 6

Metabolite and Enzyme Assays 6

Reagents 6

Biomarker Services 6

Clinical Biomarker Services 6

Biomarker Testing 6

Assay Development and Production 6

Antibody Development 7

Specimen Preparation 7

Bioinformatics and Others 7

2. INDUSTRY OVERVIEW 8

Global Biomarkers Market Surges in the Backdrop of Widening

Medical Scope and Applications 8

Factors Engendering Positive Vibes 8

Factors Engendering Positive Influence on the Biomarkers

Market: A Summary 9

Biomarkers: A Regional Perspective 9

US Spearheads the Global Biomarkers Market 9

US and Japan Take Lead on the Patent Front 10

Table 1: Dominance of US in the Global Biomarker Patent

Filings (includes corresponding Graph/Chart) 10

Table 2: Leading Players in the Biomarkers Space by Number

of Patent Filings (includes corresponding Graph/Chart) 11

Table 3: Number of Biomarker Patents Published and Filed:

2003-2007 (includes corresponding Graph/Chart) 11

Asia-Pacific: The Fastest Growing Biomarker Market 12

Supportive Governments and Regulatory Bodies to Fuel Growth 12

Increasing Collaborations Among Regulators and Companies

Augur Well for Biomarkers 12

Player Strategies: An Insight 13

Table 4: Growing Number of Biomarker Deals (includes

corresponding Graph/Chart) 13

Table 5: Competitive Strategy Mix in the Global Oncology

Biomarkers Market (includes corresponding Graph/Chart) 14

Pharma and Biomarker Developer Tie-Ups to Raise Drug

Development Productivity 14

3. MARKET OUTLOOK 15

Biomarkers: Evolving Scope and Applications 15

Technological Advancements - A Boon for Biomarker Discovery 15

Evolving Role of Biomarkers in Drug Development 16

Companion Biomarkers 16

Biomarkers Play Invaluable Role in Oncology and Cardiovascular

Disease Diagnosis 16

Personalized Medicine- Revolutionizing the Medical Treatment 17

Biomarker-Led Drug Discovery - A Profitable Investment 18

Technological Trends 18

Proteins Gain Upper Hand in Biomarkers 18

Mass Spectrometry - A Promising Technology in Molecular Medicine 18

Market Restraints 19

Challenges in Biomarker Validation - A Major Growth Retardant 19

The Road Ahead 19

Biomarkers to Witness Significant Growth in Therapeutic and

Diagnostic Arenas 19

Efficiency Improvements Must for Realizing Cost-Effective

Biomarker Testing 20

4. BIOMARKER TECHNOLOGIES AND SERVICES: AN OVERVIEW 21

Biomarker - Definition & Introduction 21

BIOMARKER TECHNOLOGIES 21

EMERGING BIOMARKER TECHNOLOGIES 21

Proteomics 22

Growth Drivers and Market Trends 22

Efficiency Gains in Drug Discovery Drive Growth in Proteomics 22

Proteomics Witness Increased Focus on Targeted Approach 22

Mass Spectrometry -Shifts in Focus to Proteomics Helps

Biomarker Development 23

Mass Spectrometry Expands Scope of Protein Biomarker

Applications 23

Transcriptomics 23

Transcriptomics - Assisting in Identification of Biomarkers 23

Imaging Biomarkers: Disease Diagnosis, the Non-Invasive way 24

Types of Imaging Biomarkers - An Overview 24

Market Trends 25

Molecular Imaging - Gaining Importance in Drug Discovery

and Development 25

Use of Molecular Imaging in Clinical Trials for Drug

Development 25

Bioinformatics 26

CONVENTIONAL BIOMARKER TECHNOLOGIES 26

Molecular Diagnostics 26

Immunodiagnostics 26

Market Trends 26

Growth in Use of Molecular Diagnostics to Propel Biomarker

Growth 26

Demand for Novel Biomarkers Persists in Immunodiagnostics 27

Immunoassays Plagued with Standardization Issues 27

OTHER BIOMARKER TECHNOLOGIES 27

Metabolite and Enzyme Assays 27

Reagents 28

Market Trends 28

Microarrays Surge Biomarker Identification 28

Metabolomics Gain Rapid Foothold in Drug Discovery 28

BIOMARKER SERVICES 28

Expanding Capabilities Drive Large-Scale Adoption 29

Clinical Biomarker Services 29

Biomarker Testing 29

Assay Development and Production 30

Antibody Development 30

Specimen Preparation 30

Bioinformatics and Other Biomarker Services 31

Bioinformatics Gain Prominence 31

miRNA Analysis 31

Microarray Services Witness Increasing Investments 31

5. BIOMARKERS MARKET BY APPLICATION 32

Role of Biomarkers in Drug Discovery and Development 32

Role of Biomarkers in Clinical Research and Patient Management 32

Major Benefits of Biomarkers in Clinical Development 33

Major Benefits of Biomarkers in Medicine 33

Multifarious Applications of Biomarkers 33

New Applications Come to the Fore 33

Application of Biomarkers in Drug Development 34

Herceptin and Vilazodone -References for Success of Biomarker

Based Approach 34

Increasing Role of Biomarkers in Modern Drug R&D 35

Translational Medicine Biomarkers Revolutionizing Drug

Development Process 35

Outsourcing - Opportunities Galore 35

CROs in a Dilemma Over Investments in Biomarker Analysis

Services 36

Lower Productivity of Traditional Drug Discovery Approach

Calls for New Methods 36

Blockbuster Model Versus Personalized Medication Model 37

Workflow Standardization - Key to Success of Biomarkers in

Drug Development 37

6. BIOMARKERS BY THERAPEUTIC AREA 38

Current & Future Analysis 38

ONCOLOGY 38

Factors Driving Oncology Biomarkers' Growth 38

US Remains at the Forefront of Cancer Biomarker Patent Filings 39

Table 6: Regional Split in the Global Cancer Biomarker

Patent Filings: 2009 (includes corresponding Graph/Chart) 39

Table 7: Leading Players in Cancer Biomarkers by Number of

Patent Filings: 2004-2009 39

Global Oncology Diagnostics and Drug Discovery Biomarkers Market 40

Table 8: World Recent Past, Current and Future Analysis for

Oncology Biomarkers Market by Geographic Region - US,

Canada, Japan, Europe, Asia-Pacific and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2008 through 2017 (includes

corresponding Graph/Chart) 41

Table 9: World 10-Year Perspective for Oncology Biomarkers

Market by Geographic Region - Percentage Breakdown of Dollar

Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest

of World Markets for Years 2008, 2011 and 2017 (includes

corresponding Graph/Chart) 42

Table 10: Global Cancer Biomarkers Diagnostics (Molecular)

Market by Company (2009): Market Share Breakdown of Revenues

for Roche, Gen-Probe, Myriad, Abbott, QIAGEN and Others

(includes corresponding Graph/Chart) 43

Evolution of Oncology Biomarkers 43

Available and Pipeline Biomarkers in Various Cancers 44

Breast Cancer Dominates Cancer Biomarkers Pipeline 44

Table 11: Global Cancer Biomarkers Pipeline by Indication

(2010): Percentage Share Breakdown for Breast Cancer,

Prostate Cancer, Colorectal Cancer, Ovarian Cancer, and

Others (includes corresponding Graph/Chart) 45

Table 12: Global Oncology Biomarkers Market: Percentage

Breakdown of Patent Filings by Oncology Area (2007) 45

Breast Cancer Market Awaits New Specific Biomarkers 45

Oncology Biomarker Diagnostic Techniques 46

Table 13: Leading Cancer Biomarker Diagnostic Technologies

(2009): Percentage Share of Value Sales for Gene-based

Markers, Proteomics, DNA Microarrays, Immunological Markers

and IHC Tests, and Others (includes corresponding

Graph/Chart) 46

Current Trends in Cancer Biomarkers 47

Validation Techniques Take Center Stage 47

Early-Stage Use of Biomarkers High in Oncology 47

Proteomics Ahead of Genomic Biomarkers in Functionality 48

Pharmacogenomics and IHC Tests Inch Ahead in Cancer

Biomarker Diagnostics 48

Faster Diagnosis Benefits DNA Microarray Technology 48

Other Tests Lose Market Share 49

Companion Biomarkers in Oncology 49

CARDIOLOGY 49

Market Trends 50

Increasing Health Burden Drives Research Efforts 50

Gene Expression Analysis Delivers Novel Therapeutic Approaches 50

High-Performance Techniques Drive Biomarker Discovery in

Cardiology 51

Effective Phenotyping Takes Precedence for Successful

Genotyping Studies 51

Role of Linkage Analysis in Cardiovascular Biomarker

Identification 51

Biomarkers of ACS 51

Biomarkers - A Promising Diagnostic Tool for ACS 52

Biomarker Discovery in Cardiovascular Diseases to Undergo

Significant Changes 52

Major Cardiovascular Diagnostic Biomarkers - A Focus on

Biomarkers for ACS 53

Creatine Kinase-Myocardial Band 53

Natriuretic Peptides 53

Cardiac Troponin 53

Myoglobin 53

New Diagnostic Biomarkers for ACS on the Anvil 54

Genomic Biomarkers for Detecting Cardiovascular Diseases 54

Growing Demand for Stroke Biomarkers 55

Rising Incidence of the Disease - A Major Driver for Stroke

Biomarkers 55

CENTRAL NERVOUS SYSTEM (CNS) 55

Lower Commercial Availability Restricts Market Share 56

Research Efforts Remain Confined to Specific Areas 56

High Cost of Treatment Shadows Biomarkers' Short-Treatment

Benefits 56

Research Methodology in CNS Biomarkers 56

Alliances - A Key Aspect to the Development of CNS Biomarkers 57

Biomarkers in Select CNS Diseases 57

Alzheimer's Disease 57

Parkinson's Disease Biomarkers - Crucial for

Neuroprotectants' Effectiveness 58

Schizophrenia: An Unexploited Segment 58

OTHER THERAPEUTIC AREAS 58

Inflammatory and Autoimmune Disorders 58

Biomarkers offer Efficient Diagnosis and Treatment 59

Rheumatology 59

7. AN OVERVIEW OF SELECT BIOMARKERS 60

HER2/neu/ ErbB2 Gene 60

HER2 and its Association with Cancer 60

Target Drugs for HER2 60

Hepsin Biomarkers 60

Early Prostate Cancer Antigen-2 60

MMP-3 61

ImmunoCyt™/uCyt+™ 61

AmpliChip CYP450 Test 62

The OncoVue® Breast Cancer Risk Test 62

Oncotype DX® Test 62

Oncotype DX Colon Cancer Assay 63

MammaPrint 63

Theros CancerTYPE ID 63

PgxPredict:CLOZAPINE- Test for Qualifying Patients to Use

Clozapine 63

The Pathwork Tissue of Origin Test 64

PROGENSA PCA3 Assay 64

Epi proColon® Early Detection Assay 64

OVA1® Test 65

Bcr-abl Fusion Protein 65

HLA-B 65

Mammostrat® 65

Ipsogen MapQuant Dx™ Genomic Grade 66

CA1-18 Enzyme Immunoassay (EIA) 66

Anti-L523S Antibody 66

8. PRODUCT INTRODUCTIONS IN THE BIOMARKERS SPACE 67

RBM Unveils OncologyMAP® Panel of 101 Quantitative Biomarker

Tests 67

Avantra Introduces New BioChip Immunoassay Biomarker Workstation 67

Clarient Introduces Mammostrat Test 67

Biomagnetics Diagnostics Identifies Second Biomarker for

Tuberculosis Assay 68

Epistem Introduces Novel Ex Vivo Plucked Hair Biomarker Assay 68

Crescendo Bioscience Launches New Multi Biomarker Blood Test 68

Alere International Launches New Triage® NT-proBNP Test 68

Agilent Technologies Launches New SureSelect Kinome Target

Enrichment Kit 69

Roche Diagnostics to Launch New STAT Immunoassays 69

Gentel Biosciences Launches New Human Profiling Kits 69

QIAGEN Introduces QIAsymphony RGQ System 70

Almac Introduces Biomarkers for Biopharmaceutical Industry 70

i-Path Introduces TMA Toolbox 71

Abbott Introduces ARCHITECTPLUS Systems 71

Affymetrix Introduces QuantiGene® ViewRNA Assayformats 72

ARUP Laboratories Introduces New Test for Colorectal Caner

Detection 72

Warnex Launches Blood Testing Service for Colorectal Cancer in

Canada 72

Agilent Technologies Launches mAb-Glyco-Chip 73

synlab Launches Septin9 Testing in Germany 73

IDBS Introduces New Biomarker Discovery and Validation Solution 73

Quest Diagnostics Introduces Blood Test for Detecting

Colorectal Cancer 74

Clarient Introduces Biomarker Panel for NSCLC Classification 74

Institute of Microelectronics and Agency for Science,

Technology and Research Launch Rapid Cardiac Biomarker Test 74

Rules-Based Medicine Unveils CardiovascularMAP™ for CVD Treatment 75

Thermo Fisher Introduces New Copeptin Assay 75

Psynova Neurotech and RBM Identify New Biomarkers for

Schizophrenia 75

Genedata Unveils Genedata Expressionist® 5.3 75

Arrayit Introduces Biomarker Discovery Service 76

Invitrogen Introduces Biomarker Tool for Kidney Function Research 76

Abbott Introduces ARCHITECT® c4000® 76

Epigenomics Rolls Out Epi proColon Range in Europe 77

Genedata Introduces Expressionist 5.2 for Identifying MS-based

Biomarker 77

VisEn Unveils FAST - A Novel Imaging Platform 77

Millipore and CXR Biosciences Unveils ToxReporter™ 78

Rules-Based Medicine Unveils Human Kidney Multi-Analyte Profile 78

MDS and Applied Biosystems Launch AB SCIEX TOF/TOF™ 5800 System 78

Genetic Biomarkers for Chronic Kidney Disease 79

Bruker Launches Advanced MALDI-TOF/TOF Mass Spectrometer 79

Satoris Introduces three Novel Blood Tests 79

GE Healthcare Launches Discovery™ MR450 79

GE Healthcare in Partnership with Varian Launches Discovery

MR901 (US) 80

Applied Biosystems and MDS Analytical Launches Novel New Mass

Spectrometry Tools 80

Rules-Based Medicine Commercializes Rat Kidney MAP Biomarker

Panel 80

Thomson Reuters Introduces BIOMARKERcenter 81

Gentel® Biosciences Introduces SilverQuant™ GlycoBiomarker

Array Kit 81

BioMarker Pharmaceuticals Introduces Gene Essence™ DNA Test 82

mtm laboratories Introduces Cervatec™ Assay 82

Decision Biomarkers Introduces AVANTRA Biomarker Workstation 82

Aureon Introduces Prostate Px® to Predict Progression and

Recurrence of Prostrate cancer 83

VisEn Introduces a Novel Imaging Agent 83

9. BIOMARKERS M&A ACTIVITY 84

QIAGEN to Take Over Stake in Alacris Theranostics 84

Transgenomic Acquires Certain Businesses of Clinical Data 84

Caliper Life Sciences Acquires Cambridge Research &

Instrumentation 84

Biosystems International and MicroBioChips Merge 85

Axela Takes Over Xceed Molecular 85

Accelrys Merges with Symyx Technologies 85

Caprion Proteomics Acquires PPD's Biomarker Division 86

QIAGEN Takes Over SABiosciences 86

Thermo Fisher Scientific Takes Over Brahms 86

QIAGEN Takes Over DxS 87

ICON Takes Over Veeda Laboratories 87

ID Business Solutions Takes Over InforSense 87

Clinical Data Acquires Avalon Pharmaceuticals 88

Genetix Takes Over SlidePath 88

Oxford Gene Technology Takes Over Sense Proteomic 88

Tethys Bioscience Takes Over Lipomics Technologies 88

QPS LLC Acquires Bio-Kinetic Clinical Applications 89

AltheaDx Rolls Out Affymetrix DMET Genotyping Microarray Service 89

10. COLLABORATIONS AND AGREEMENTS 90

Proteome Sciences Bags Contract from Eisai 90

MDxHealth to Ink Partnership Agreement with Pfizer, Cancer

Research Technology and Newcastle University 90

Takeda and Zinfandel Enter into License Agreement for AD

Biomarker 90

Pacific Biomarkers Forges Research Deals with Two

Multinational Firms 90

SMA Foundation and RBM Partner to Develop Panel of SMA Biomarker 91

Epigenomics Enters into Collaboration with QIAGEN to Develop

Colorectal Cancer Blood Tests 91

Vermillion Inks Agreement with Quest to Launch OVA1® in India 91

DiaGenic and Pfizer Team Up for Identifying Biomarkers for AD 92

Prometheus Signs Agreement with The Regents of the University

of California 92

Aushon BioSystems Enters into Partnership with LightArray Biotech 92

GE Healthcare Collaborates with Johnson & Johnson 93

ICON Enters into Strategic Alliance with Proteome Sciences 93

Epigenomics Inks Distribution Agreement with DATEKS 93

Epigenomics Inks Distribution Agreement with Pronto Diagnostics 93

Thermo Fisher Collaborates with Proteome Sciences 94

Diaceutics Teams Up with London Genetics to Develop Software

Decision Tools 94

OncoMethylome Enters Into Agreement with GlaxoSmithKline

Biologicals 94

SureGene Enters into Research Collaboration with Medco

Research Institute 95

Ariadne Inks Agreement with Roswell Park Cancer Institute and

Cellecta 95

SDIX Enters into Multi-Year Collaboration with Banyan Biomarkers 96

Roche Acquires Co-exclusive License from QIAGEN 96

Metabolon Collaborates with Colgate-Palmolive for Periodontal

Disease Biomarkers Identification 96

Toscana Biomarkers and Regione Toscana Enter into Grant Agreement 96

ACC and Roche Diagnostics Initiate Collaboration 97

Epigenomics Inks Distribution Agreement with DPC LEBANON 97

Duke Enters into Joint Venture with LabCorp for Biomarker

Commercialization 97

HDC and SPM Enter Into Agreement with Quest Diagnostics 98

Toscana Biomarkers Collaborates with QuantiScientifics 98

Intrinsic Bioprobes Licenses New Biomarkers to Ortho-Clinical

Diagnostics 98

Shimadzu Allies with Nonlinear Dynamics and Ceres Nanosciences 99

PAREXEL Enters into Partnership with Proteome Sciences 99

Biocartis Inks Agreement with Royal Philips Electronics 99

QIAGEN Signs Agreement with Wuxi AppTec 100

SDIX Enters into Collaboration with Fred Hutchinson Cancer

Research Center 100

Siemens Teams UP with EDPL to Institute Cyclotron Facility in

India 100

ALS TDI Concluded First Phase of Collaboration with Applied

Proteomics 101

Psynova Neurotech Teams Up with Roche for Schizophrenia

Treatment Development 101

Minerva Biotechnologies Licenses Exclusive Marketing Rights to

Clarient 102

Rules-Based Medicine Signs Biomarker-Driven Agreement with

Covance 102

BG Medicine and Abbott Ink Agreement for galectin-3 Biomarker 102

Epigenomics and ARUP Ink Non-Exclusive Agreement 102

Biosystems International Signs Licensing Agreement with

Lohocla Research 102

Axela Signs Agreements with Micromedics and Proteome Sciences 103

Moffitt Cancer Center and Frantz BioMarkers Enter into

Licensing Agreement 103

Fujirebio Diagnostics Signs Agreement with BD for Oncology

Diagnostic Assays 104

Quest Diagnostics Bags Prostrate Cancer Test License from

Epigenomics 104

Genedata Extends Collaboration Agreement with Roche 104

BioTheranostics Inks Commercialization Agreement with Lab 21

for THEROS CancerTYPE ID 104

Researchers Utilizes AB Sciex Qtrap 5500 System to Detect

Biomarkers 105

Fujirebio Inks Agreement with Abbott to Develop Ovarian Cancer

Test 105

Caprion and Applied Bioystems Partners to Accelerate

Validation and Verification of Protein Biomarker 105

Sysmex Inks Research Partnership Deal with Epigenomics 106

Pharsight Inks Agreement with InforSense 106

AstraZeneca and Washington University Team Up to Develop Novel

Methods for Alzheimer's Disease Diagnosis and Treatment 106

11. OTHER CORPORATE INITIATIVES IN BIOMARKERS SPACE 107

Genedata Installs Genedata Expressionist® Refiner MS at

Victoria DPI 107

Genedata Deploys Genedata Expressionist® at Hospital for Sick

Children 107

Covance Establishes New Unit for Discovery and Translation

Services 107

The University of Liège Spins-off Targetome Business 107

PMDA Accepts Biomarker Panel of Critical Path's 107

Clarient Obtains UK Patents for the TLE3 Biomarker 108

Agilent Supplies Mass Spectrometry Devices to Stemina

Biomarker Discovery 108

Pacific Biomarkers to Launch New Logo, Marketing and Branding

Initiatives 108

SMA Foundation Completes Biomarker Study 108

Genedata Offers Genedata Expressionist® to RIKEN 109

Chronix Biomedical Strengthens Biomarker Development Capabilities 109

Aureon Changes Name of Colorectal Cancer Prognostic Test 109

Satoris Gains Global Distribution Rights to RBM's

DiscoveryMAP™ Panel 109

Teva Pharmaceutical Industries to Use Biomarkers of Compugen 110

Genedata Provides Genedata Expressionist® System to Asubio Pharma 110

InforSense Aids Biomarker Discovery Process by Celera 110

Xennex Provides Satoris with Access to GeneCards® 111

IME Developed Silicon-Based Testing System for Cardiac Biomarkers 111

12. FOCUS ON SELECT GLOBAL PLAYERS 112

Abbott Laboratories (US) 112

Affymetrix, Inc. (US) 112

Agilent Technologies, Inc. (US) 113

Alexion Pharmaceuticals, Inc. (USA) 113

Beckman Coulter, Inc. (US) 114

Becton, Dickinson and Company (US) 114

Bio-Rad Laboratories, Inc. (US) 115

BioMerieux (France) 115

Bruker Corporation (US) 115

Caprion Proteomics, Inc. (Canada) 116

Clarient Inc. (US) 117

Compugen, Ltd. (Israel) 117

Correlogic Systems, Inc. (US) 117

DiagnoCure, Inc. (Canada) 117

Epigenomics AG (Germany) 118

GE Healthcare (UK) 118

Gene Logic (US) 119

Genedata AG (Switzerland) 119

Gen-Probe Inc. (US) 119

GlaxoSmithKline Plc. (UK) 120

Hitachi Medical Corporation (Japan) 120

Illumina, Inc. (US) 121

LabCorp. (US) 121

Life Technologies Corporation (US) 122

Merck & Co., Inc. (US) 122

Metabolon, Inc. (US) 122

Myriad Genetics, Inc. (US) 123

Novartis International AG (Switzerland) 123

Panacea Laboratories (US) 124

Pfizer, Inc. (US) 124

Philips Healthcare (Netherlands) 125

QIAGEN NV (The Netherlands) 125

Quest Diagnostic, Inc. (US) 125

Roche Diagnostics Corp. (US) 126

Rubicon Genomics, Inc. (US) 126

Rules-Based Medicine, Inc. (US) 126

Siemens Healthcare Diagnostics, Inc. (US) 127

13. GLOBAL MARKET PERSPECTIVE 128

Table 14: World Recent Past, Current and Future Analysis for

Biomarkers by Geographic Region - US, Canada, Japan, Europe,

Asia-Pacific and Rest of World Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2008

through 2017 (includes corresponding Graph/Chart) 128

Table 15: World 10-Year Perspective for Biomarkers by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific and Rest of World

Markets for Years 2008, 2011 and 2017 (includes corresponding

Graph/Chart) 129

Table 16: World Recent Past, Current and Future Analysis for

Biomarker Technologies by Geographic Region - US, Canada,

Japan, Europe, Asia-Pacific and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2008 through 2017 (includes corresponding

Graph/Chart) 130

Table 17: World 10-Year Perspective for Biomarker Technologies

by Geographic Region - Percentage Breakdown of Dollar Sales

for US, Canada, Japan, Europe, Asia-Pacific and Rest of World

Markets for Years 2008, 2011 and 2017 (includes corresponding

Graph/Chart) 131

Table 18: World Recent Past, Current and Future Analysis for

Biomarker Technologies by Segment - Emerging Biomarker

Technologies, Conventional Biomarker Technologies, and Other

Biomarker Technologies Markets Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2008 through

2017 (includes corresponding Graph/Chart) 132

Table 19: World 10-Year Perspective for Biomarker Technologies

by Segment - Percentage Breakdown of Dollar Sales for Emerging

Biomarker Technologies, Conventional Biomarker Technologies,

and Other Biomarker Technologies Markets for Years 2008, 2011

and 2017 (includes corresponding Graph/Chart) 132

Table 20: World Recent Past, Current and Future Analysis for

Emerging Biomarker Technologies by Geographic Region - US,

Canada, Japan, Europe, Asia-Pacific and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2008 through 2017 (includes corresponding

Graph/Chart) 133

Table 21: World 10-Year Perspective for Emerging Biomarker

Technologies by Geographic Region - Percentage Breakdown of

Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and

Rest of World Markets for Years 2008, 2011 and 2017 (includes

corresponding Graph/Chart) 134

Table 22: World Recent Past, Current and Future Analysis for

Emerging Biomarker Technologies by Segment - Imaging

biomarkers, Proteomics, Transcriptomics, and Bioinformatics

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2008 through 2017 (includes

corresponding Graph/Chart) 135

Table 23: World 10-Year Perspective for Emerging Biomarker

Technologies by Segment - Percentage Breakdown of Dollar Sales

for Imaging biomarkers, Proteomics, Transcriptomics, and

Bioinformatics Markets for Years 2008, 2011 and 2017 (includes

corresponding Graph/Chart) 135

Table 24: World Recent Past, Current and Future Analysis for

Imaging Biomarkers by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2008 through 2017 (includes corresponding Graph/Chart) 136

Table 25: World 10-Year Perspective for Imaging Biomarkers by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific and Rest of World

Markets for Years 2008, 2011 and 2017 (includes corresponding

Graph/Chart) 137

Table 26: World Recent Past, Current and Future Analysis for

Proteomics in Biomarkers Market by Geographic Region - US,

Canada, Japan, Europe, Asia-Pacific and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2008 through 2017 (includes corresponding

Graph/Chart) 138

Table 27: World 10-Year Perspective for Proteomics in

Biomarker Market by Geographic Region - Percentage Breakdown

of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific

and Rest of World Markets for Years 2008, 2011 and 2017

(includes corresponding Graph/Chart) 139

Table 28: World Recent Past, Current and Future Analysis for

Transcriptomics in Biomarkers Market by Geographic Region -

US, Canada, Japan, Europe, Asia-Pacific and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2008 through 2017 (includes

corresponding Graph/Chart) 140

Table 29: World 10-Year Perspective for Transcriptomics in

Biomarkers Market by Geographic Region - Percentage Breakdown

of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific

and Rest of World Markets for Years 2008, 2011 and 2017

(includes corresponding Graph/Chart) 141

Table 30: World Recent Past, Current and Future Analysis for

Bioinformatics in Biomarkers Market by Geographic Region - US,

Canada, Japan, Europe, Asia-Pacific and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2008 through 2017 (includes corresponding

Graph/Chart) 142

Table 31: World 10-Year Perspective for Bioinformatics in

Biomarkers Market by Geographic Region - Percentage Breakdown

of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific

and Rest of World Markets for Years 2008, 2011 and 2017

(includes corresponding Graph/Chart) 143

Table 32: World Recent Past, Current and Future Analysis for

Conventional Biomarker Technologies by Geographic Region - US,

Canada, Japan, Europe, Asia-Pacific and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2008 through 2017 (includes corresponding

Graph/Chart) 144

Table 33: World 10-Year Perspective for Conventional Biomarker

Technologies by Geographic Region - Percentage Breakdown of

Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and

Rest of World Markets for Years 2008, 2011 and 2017 (includes

corresponding Graph/Chart) 145

Table 34: World Recent Past, Current and Future Analysis for

Conventional Biomarker Technologies by Segment -

Immunodiagnostics and Molecular Diagnostics Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2008 through 2017 (includes corresponding

Graph/Chart) 146

Table 35: World 10-Year Perspective for Conventional Biomarker

Technologies by Segment - Percentage Breakdown of Dollar Sales

for Immunodiagnostics and Molecular Diagnostics Markets for

Years 2008, 2011, and 2017 (includes corresponding

Graph/Chart) 146

Table 36: World Recent Past, Current and Future Analysis for

Immunodiagnostics by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2008 through 2017 (includes corresponding Graph/Chart) 147

Table 37: World 10-Year Perspective for Immunodiagnostics by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific and Rest of World

Markets for Years 2008, 2011 and 2017 (includes corresponding

Graph/Chart) 148

Table 38: World Recent Past, Current and Future Analysis for

Molecular Diagnostics by Geographic Region - US, Canada,

Japan, Europe, Asia-Pacific and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2008 through 2017 (includes corresponding

Graph/Chart) 149

Table 39: World 10-Year Perspective for Molecular Diagnostics

by Geographic Region - Percentage Breakdown of Dollar Sales

for US, Canada, Japan, Europe, Asia-Pacific and Rest of World

Markets for Years 2008, 2011 and 2017 (includes corresponding

Graph/Chart) 150

Table 40: World Recent Past, Current and Future Analysis for

Other Biomarker Technologies by Geographic Region - US,

Canada, Japan, Europe, Asia-Pacific and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2008 through 2017 (includes corresponding

Graph/Chart) 151

Table 41: World 10-Year Perspective for Other Biomarker

Technologie by Geographic Region - Percentage Breakdown of

Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and

Rest of World Markets for Years 2008, 2011 and 2017 (includes

corresponding Graph/Chart) 152

Table 42: World Recent Past, Current and Future Analysis for

Biomarker Services by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2008 through 2017 (includes corresponding Graph/Chart) 153

Table 43: World 10-Year Perspective for Biomarker Services by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Canada, Japan, Europe, Asia-Pacific and Rest of World

Markets for Years 2008, 2011 and 2017 (includes corresponding

Graph/Chart) 154

Table 44: World Recent Past, Current and Future Analysis for

Biomarker Services by Segment- Clinical Biomarker Services,

Specimen Preparation, and Other Biomarker Services Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2008 through 2017 (includes corresponding

Graph/Chart) 155

Table 45: World 10-Year Perspective for Biomarker Services by

Segment - Percentage Breakdown of Dollar Sales for Clinical

Biomarker Services, Specimen Preparation, and Other Biomarker

Services Markets for Years 2008, 2011 and 2017 (includes

corresponding Graph/Chart) 155

Table 46: World Recent Past, Current and Future Analysis for

Clinical Biomarker Services by Geographic Region - US, Canada,

Japan, Europe, Asia-Pacific and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2008 through 2017 (includes corresponding

Graph/Chart) 156

Table 47: World 10-Year Perspective for Clinical Biomarker

Services by Geographic Region - Percentage Breakdown of Dollar

Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of

World Markets for Years 2008, 2011 and 2017 (includes

corresponding Graph/Chart) 157

Table 48: World Recent Past, Current and Future Analysis for

Specimen Preparation by Geographic Region - US, Canada, Japan,

Europe, Asia-Pacific and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2008 through 2017 (includes corresponding Graph/Chart) 158

Table 49: World 10-Year Perspective for Specimen Preparation

by Geographic Region - Percentage Breakdown of Dollar Sales

for US, Canada, Japan, Europe, Asia-Pacific and Rest of World

Markets for Years 2008, 2011 and 2017 (includes corresponding

Graph/Chart) 159

Table 50: World Recent Past, Current and Future Analysis for

Other Biomarker Services by Geographic Region - US, Canada,

Japan, Europe, Asia-Pacific and Rest of World Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2008 through 2017 (includes corresponding

Graph/Chart) 160

Table 51: World 10-Year Perspective for Other Biomarker

Services by Geographic Region - Percentage Breakdown of Dollar

Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of

World Markets for Years 2008, 2011 and 2017 (includes

corresponding Graph/Chart) 161

Table 52: World Recent Past, Current and Future Analysis for

Biomarkers by Application - Biomarker Discovery, Clinical Drug

Development, and Diagnostics Techniques (Molecular) Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2008 through 2017 (includes corresponding

Graph/Chart) 162

Table 53: World 10-Year Perspective for Biomarkers by

Application - Percentage Breakdown of Dollar Sales for

Biomarker Discovery, Clinical Drug Development, and

Diagnostics Techniques (Molecular) Markets for Years 2008,

2011 and 2017 (includes corresponding Graph/Chart) 162

Table 54: World Recent Past, Current and Future Analysis for

Biomarkers by Therapeutic Area - Cancer Biomarkers, Cardiology

Biomarkers, CNS Biomarkers, and Other Therapeutic Biomarker

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2008 through 2017 (includes

corresponding Graph/Chart) 163

Table 55: World 10-Year Perspective for Biomarkers by

Therapeutic Area - Percentage Breakdown of Dollar Sales for

Cancer Biomarkers, Cardiology Biomarkers, CNS Biomarkers, and

Other Therapeutic Biomarker Markets for Years 2008, 2011 and

2017 (includes corresponding Graph/Chart) 164

14. THE UNITED STATES 165

A.Market Analysis 165

Current & Future Analysis 165

Companies Wake Up to the Growing Need for Effective Biomarkers 165

Biomarker Regulations in the US 166

Product Launches 166

Strategic Corporate Developments 176

Focus on Select Major Players 189

B.Market Analytics 201

Table 56: The US Recent Past, Current and Future Analysis

for Biomarkers by Segment-Biomarker Technologies [Emerging

Biomarker Technologies (Imaging Biomarkers, Proteomics,

Transcriptomics and Bioinformatics), Conventional Biomarker

Technologies (Immunodiagnostics and Molecular Diagnostics)

and Others] and Biomarker Services [Clinical Biomarker

Services, Specimen Preparation and Others] Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2008 through 2017 (includes corresponding

Graph/Chart) 201

Table 57: The US 10-Year Perspective for Biomarkers by

Segment - Percentage Breakdown of Dollar Sales for Biomarker

Technologies [Emerging Biomarker Technologies (Imaging

Biomarkers, Proteomics, Transcriptomics and Bioinformatics),

Conventional Biomarker Technologies (Immunodiagnostics and

Molecular Diagnostics) and Others] and Biomarker Services

[Clinical Biomarker Services, Specimen Preparation and

Others] Markets for Years 2008, 2011 and 2017 (includes

corresponding Graph/Chart) 203

15. CANADA 204

A.Market Analysis 204

Current & Future Analysis 204

Product Launch 204

Strategic Corporate Developments 204

Focus on Select Major Players 206

B.Market Analytics 207

Table 58: Canadian Recent Past, Current and Future Analysis

for Biomarkers by Segment- Biomarker Technologies [Emerging

Biomarker Technologies (Imaging Biomarkers, Proteomics,

Transcriptomics and Bioinformatics), Conventional Biomarker

Technologies (Immunodiagnostics and Molecular Diagnostics)

and Others] and Biomarker Services [Clinical Biomarker

Services, Specimen Preparation and Others] Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2008 through 2017 (includes corresponding

Graph/Chart) 207

Table 59: Canadian 10-Year Perspective for Biomarkers by

Segment - Percentage Breakdown of Dollar Sales for Biomarker

Technologies [Emerging Biomarker Technologies (Imaging

Biomarkers, Proteomics, Transcriptomics and Bioinformatics),

Conventional Biomarker Technologies (Immunodiagnostics and

Molecular Diagnostics) and Others] and Biomarker Services

[Clinical Biomarker Services, Specimen Preparation and

Others] Markets for Years 2008, 2011 and 2017 (includes

corresponding Graph/Chart) 209

16. JAPAN 210

A.Market Analysis 210

Current & Future Analysis 210

Strategic Corporate Developments 210

Hitachi Medical Corporation - A Key Player 211

B.Market Analytics 212

Table 60: Japanese Recent Past, Current and Future Analysis

for Biomarkers by Segment- Biomarker Technologies [Emerging

Biomarker Technologies (Imaging Biomarkers, Proteomics,

Transcriptomics and Bioinformatics), Conventional Biomarker

Technologies (Immunodiagnostics and Molecular Diagnostics)

and Others] and Biomarker Services [Clinical Biomarker

Services, Specimen Preparation and Others] Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2008 through 2017 (includes corresponding

Graph/Chart) 212

Table 61: Japanese 10-Year Perspective for Biomarkers by

Segment - Percentage Breakdown of Dollar Sales for Biomarker

Technologies [Emerging Biomarker Technologies (Imaging

Biomarkers, Proteomics, Transcriptomics and Bioinformatics),

Conventional Biomarker Technologies (Immunodiagnostics and

Molecular Diagnostics) and Others] and Biomarker Services

[Clinical Biomarker Services, Specimen Preparation and

Others] Markets for Years 2008, 2011 and 2017 (includes

corresponding Graph/Chart) 214

17. EUROPE 215

A.Market Analysis 215

Current & Future Analysis 215

Biopharmaceutical Industry Tunes into Biomarker- Based Drug R&D 215

Biomarker Regulations in Europe 215

EMEA's Experience in Pharmacogenetic Drugs - Still Nascent 216

Uncertain Laws Discourage VC Funding in Europe 216

Uncertainty Continues Among Regulators over Biomarker

Validation Levels 216

B.Market Analytics 217

Table 62: European Recent Past, Current and Future Analysis

for Biomarkers by Geographic Region - France, Germany,

Italy, UK and Rest of Europe Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2008

through 2017 (includes corresponding Graph/Chart) 217

Table 63: European 10-Year Perspective for Biomarkers by

Geographic Region - Percentage Breakdown of Dollar Sales for

France, Germany, Italy, UK and Rest of Europe Markets for

Years 2008, 2011 and 2017 (includes corresponding

Graph/Chart) 218

Table 64: European Recent Past, Current and Future Analysis

for Biomarkers by Segment- Biomarker Technologies [Emerging

Biomarker Technologies (Imaging Biomarkers, Proteomics,

Transcriptomics and Bioinformatics), Conventional Biomarker

Technologies (Immunodiagnostics and Molecular Diagnostics)

and Others] and Biomarker Services [Clinical Biomarker

Services, Specimen Preparation and Others] Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2008 through 2017 (includes corresponding

Graph/Chart) 219

Table 65: European 10-Year Perspective for Biomarkers by

Segment - Percentage Breakdown of Dollar Sales for Biomarker

Technologies [Emerging Biomarker Technologies (Imaging

Biomarkers, Proteomics, Transcriptomics and Bioinformatics),

Conventional Biomarker Technologies (Immunodiagnostics and

Molecular Diagnostics) and Others] and Biomarker Services

[Clinical Biomarker Services, Specimen Preparation and

Others] Markets for Years 2008, 2011 and 2017 (includes

corresponding Graph/Chart) 221

17a. FRANCE 222

A.Market Analysis 222

Current & Future Analysis 222

Strategic Corporate Development 222

BioMérieux (France) - A Key Player 222

B.Market Analytics 223

Table 66: French Recent Past, Current and Future Analysis

for Biomarkers by Segment- Biomarker Technologies [Emerging

Biomarker Technologies (Imaging Biomarkers, Proteomics,

Transcriptomics and Bioinformatics), Conventional Biomarker

Technologies (Immunodiagnostics and Molecular Diagnostics)

and Others] and Biomarker Services [Clinical Biomarker

Services, Specimen Preparation and Others] Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2008 through 2017 (includes corresponding

Graph/Chart) 223

Table 67: French 10-Year Perspective for Biomarkers by

Segment - Percentage Breakdown of Dollar Sales for Biomarker

Technologies [Emerging Biomarker Technologies (Imaging

Biomarkers, Proteomics, Transcriptomics and Bioinformatics),

Conventional Biomarker Technologies (Immunodiagnostics and

Molecular Diagnostics) and Others] and Biomarker Services

[Clinical Biomarker Services, Specimen Preparation and

Others] Markets for Years 2008, 2011 and 2017 (includes

corresponding Graph/Chart) 225

17b. GERMANY 226

A.Market Analysis 226

Current & Future Analysis 226

Product Launches 226

Strategic Corporate Development 227

Epigenomics AG - A Key Player 227

B.Market Analytics 228

Table 68: German Recent Past, Curr

To order this report:

Genomics Industry: Global Biomarkers Industry

Genomics Business News

More  Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. Global High Throughput Screening (HTS) Industry
2. Global Metabolomics Industry
3. Global Molecular Cytogenetics Industry
4. BioStorage Technologies, Inc. to Hold Global Sample Management Benchmarking Symposium in Conjunction With 2011 IIR Biorepositories Conference
5. ChromaDex to Present at the Rodman & Renshaw Annual Global Investment Conference
6. Hadasit to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13, 2011
7. Life Technologies to Present at the UBS 2011 Global Life Sciences Conference
8. Jeunesse Global Announces New Medical Advisory Board Member and Admittance Into the Direct Selling Association (DSA).
9. IndiaMART.com to Step Up B2B Matchmaking at Global Trade Events
10. FMC Corporation Announces Exclusive Global Development and Supply Agreements for Chr. Hansen Biological Products
11. Biochips Market (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Trends & Global Forecast (2010-2015)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... NC (PRWEB) , ... June 27, 2016 , ... ... mission to bring innovative medical technologies, services and solutions to the healthcare market. ... and implementation of various distribution, manufacturing, sales and marketing strategies that are necessary ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
Breaking Biology Technology:
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
Breaking Biology News(10 mins):